Literature DB >> 26437312

Management of opioid-dependent patients: comparison of the cost associated with use of buprenorphine/naloxone or methadone, and their interactions with concomitant treatments for infectious or psychiatric comorbidities.

Carlos Roncero1, Raquel Domínguez-Hernández, Tomás Díaz, José Manuel Fernández, Rafael Forcada, José Manuel Martínez, Pedro Seijo, Antonio Terán, Itziar Oyagüez.   

Abstract

The objective was to estimate the annual interaction management cost of agonist opioid treatment (AOT) for opioid-dependent (OD) patients with buprenorphine-naloxone (Suboxone®) (B/N) or methadone associated with concomitant treatments for infectious (HIV) or psychiatric comorbidities. A costs analysis model was developed to calculate the associated cost of AOT and interaction management. The AOT cost included pharmaceutical costs, drug preparation, distribution and dispensing, based on intake regimen (healthcare center or take-home) and type and frequency of dispensing (healthcare center or pharmacy), and medical visits. The cost of methadone also included single-dose bottles, monthly costs of custody at pharmacy, urine toxicology drug screenings and nursing visits. Potential interactions between AOT and concomitant treatments (antivirals, antibacterials/antifungals, antipsychotics, anxiolytics, antidepressant and anticonvulsants), were identified to determine the additional use of healthcare resources for each interaction management. The annual cost per patient of AOT was €1,525.97 for B/N and €1,467.29 for methadone. The average annual cost per patient of interaction management was €257.07 (infectious comorbidities), €114.03 (psychiatric comorbidities) and €185.55 (double comorbidity) with methadone and €7.90 with B/N in psychiatric comorbidities. Total annual costs of B/N were €1,525.97, €1,533.87 and €1,533.87 compared to €1,724.35, €1,581.32 and €1,652.84 for methadone per patient with infectious, psychiatric or double comorbidity respectively.Compared to methadone, the total cost per patient with OD was lower with B/N (€47.45-€198.38 per year). This is due to the differences in interaction management costs associated with the concomitant treatment of infectious and/or psychiatric comorbidities.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26437312

Source DB:  PubMed          Journal:  Adicciones        ISSN: 0214-4840            Impact factor:   2.979


  1 in total

1.  Perception of a New Prolonged-Release Buprenorphine Formulation in Patients with Opioid Use Disorder: The PREDEPO Study.

Authors:  Francisco Salvador Pascual; Alvaro Muñoz; Rodrigo Oraa; Gerardo Flórez; Pilar Notario; Pedro Seijo; Begoña Gonzalvo; Carla Assaf; Manuel Gómez; Miguel Ángel Casado
Journal:  Eur Addict Res       Date:  2021-11-01       Impact factor: 4.000

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.